This article is more than 5 years old. Information may no longer be current.
VIDEO: William J. Gradishar, MD, FASCO, FACP, reviews benefits, role of CDK 4/6 inhibitors
Results of the phase 2, single-arm MONARCH1 trial of abemaciclib demonstrated safety and efficacy and provided context in regard to how it fits in with other CDK 4/6 inhibitors, according to William J. Gradishar, MD, FASCO, FACP, of Northwestern University.
Gradishar reviews the monotherapy activity of abemaciclib (Eli Lilly) and the agent’s side effect profile. He also contrasts the results with findings regarding palbociclib (Ibrance, Pfizer).
“What was intriguing … is that you can continue dosing daily without interruption. The toxicity profile also appears to be somewhat different,” Gradishar said.
Ribociclib (LEE011, Novartis) is another CDK 4/6 inhibitor in development.
“How we use these drugs and in what setting we use these drugs will be, really, a challenge for us as we try to determine what’s optimal for each patient we see,” he said.